CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia (IB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Daniel is an Associate Professor II of Biochemistry (Livre-Docente, MS 5.2) with expertise in mass spectrometrybased proteomic analysis (shotgun proteomics) and in silico systems biology, applied to clinical and preclinical models related to psychiatric disorders.He is an elected member of the General Faculty Bench of the Unicamp's University Council (CONSU) (20252027); between 20232025, he was the most voted MS5 faculty representative at CONSU. He served as one of the Coordinators of the Biology Area at FAPESP (20182025) and as a Member of the CNPq Advisory Committee, CA-BF (20222025). He was elected Affiliate Member of the Brazilian Academy of Sciences (20172021) and of the São Paulo State Academy of Sciences (20192023). He was Faculty Advisor to the Office of the Vice President for Research at Unicamp (20172021) and Head of the Department of Biochemistry and Tissue Biology (20222024).He established the Laboratory of Neuroproteomics in 2014, after returning from Germany, where he worked for two years as Principal Investigator at LMU Ludwig Maximilians Universität München (20122014). Daniel graduated in Biology (2003) and earned his PhD in Biochemistry (2008) at Unicamp. His postdoctoral training took place at the Max Planck Institute of Psychiatry in Germany (20082010) and at the University of Cambridge, UK (20102012), where he also led the Mass Spectrometry Group at the Cambridge Centre for Neuropsychiatric Research (CCNR). During the same period, he was a consultant for Psynova Neurotech Ltd. Daniel is a Founding Member of BrProt (2012) and served as a Board Member of BrMass (20142023). He was elected to the Council of the Human Proteome Organisation (20152017) and has been part of the Steering Committee of the Human Brain Proteome Project since 2015, serving as its Chair in 2023.He is Associate Editor of npj Schizophrenia (Nature), serves on the editorial boards of eight other scientific journals, and is permanent editor of the book series Proteomics, Metabolomics, Interactomics and Systems Biology (Springer-Nature, USA). He has delivered more than 60 oral presentations at international conferences, including as Plenary Speaker, Keynote Speaker, and Chair. His metrics include H-index 39 (ISI) and H-index 51 (Google Scholar), with more than 9,600 citations (Scholar). (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Depression due to inflammation |
| Depresión por inflamación |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Psychiatric disorders rank among the most disabling health conditions worldwide, with Major Depressive Disorder (MDD) being the most prevalent and socially burdensome. Despite the availability of pharmacological treatments, a substantial proportion of patients either do not respond or only partially benefit from existing therapies, highlighting the urgent need to better understand the und…
Depression is a multifactorial and highly prevalent disorder with a significant socioeconomic impact and unsatisfactory therapeutic response in a considerable portion of patients. Its pathophysiology involves a complex network of neurobiological alterations, including dysfunctions in energy metabolism, neuroinflammation, and synaptic communication-processes in which neurons and astrocytes…
Depression is a global cause of disability, affecting over 264 million people worldwide. In mice, the chronic exposure to a dominant conspecific, named social stress, is often used as a model to mimic behavioral outcomes perceived as "depression-like" responses. Although depression is highly studied, we are yet trying to understand the neural circuit changes or malfunctions that would lea…
Major Depressive Disorder (MDD) stands as a significant contributor to worldwide disability, impacting approximately 20% of people at some point in their lives. MDD is a complex condition characterized by a diverse array of symptoms and its current treatment is mostly pharmacological. The limited response of MDD patients to antidepressants is the main clinical issue for medication adheren…
This equipment will enable the establishment of a lipidomic platform for the study of brain diseases, in particular psychiatric disorders. This equipment will be combined with the mass spectrometer also funded by FAPESP (2014 / 10068-4). (AU)
(Only some records are available in English at this moment)
The COVID-19 pandemic was initiated by the rapid spread of a SARS-CoV-2 strain. Though mainly classified as a respiratory disease, SARS-CoV-2 infects multiple tissues throughout the human body, leading to a wide range of symptoms in patients. To better understand how SARS-CoV-2 affects the proteome from cells with different ontologies, this work generated an infectome atlas of 9 cell mode…
Schizophrenia is a severe mental disorder that affects 0.7% of the worldwide population. The interactions between genetic and environment factors seem to be responsible for alterations in neurodevelopment, resulting in the manifestation of schizophrenia in late adolescence to early adulthood. The pathophysiology of schizophrenia is highly complex and involves several neurotransmission sys…
(Only some records are available in English at this moment)
Psychosis is a clinical syndrome associated with impairments across multiple domains and is a hallmark feature of the schizophrenia spectrum and other psychotic disorders. Antipsychotics are the main treatment for psychotic disorders, including schizophrenia. Despite their benefits and the improvement in patients quality of life, treatment with atypical antipsychotics may lead to undesira…
Major Depressive Disorder (MDD) is associated with high morbidity and mortality due to the increased risk of suicide and the occurrence of comorbidities such as obesity and cardiovascular diseases. In addition to the significant impact on the lives of affected individuals and their families, MDD represents an important socioeconomic burden, compromising academic and professional performan…
The Major Depressive Disorder (MDD) is characterized by depressive mood and anhedonia, affecting almost 280 million people worldwide. In children and adolescents, irritability may substitute sadness as a cardinal symptom. Recently, both proteomics and metabolomics have been applied to the identification of potential biomarkers for adults with MDD. However, the use of omic approaches to th…
(Only some records are available in English at this moment)
Depression is considered the fourth leading cause of premature death and disability. This disease is commonly associated with depressed mood, anhedonia, changes in behavior and appetite, and reduced productivity at work. The main treatment is the administration of antidepressants from different classes. However, it is observed that up to 30% of patients using antidepressants do not experi…
Neurodegenerative diseases (NDs) are characterized by neuronal loss and may be accompanied by protein abnormalities. These diseases do not yet have efficient treatments and tend to increase with population aging, making them important targets for study. Microglia are essential for maintaining homeostasis in the central nervous system (CNS), as well as actively participating in various phy…
(Only some records are available in English at this moment)
Psychiatric disorders like schizophrenia and depression have common underlying mechanisms including glutamatergic dysfunction, neuroinflammation, mitochondrial dysfunction, and their crosstalk. Impairment in autophagy, a cell survival process essential for cellular, energy and metabolic homeostasis, has been linked to these alterations. A promising drug candidate for psychiatric disorders…
Antipsychotics are a group of drugs used mainly to treat psychotic disorders like schizophrenia. Generally, they act as dopamine receptor agonists but also can affect adrenergic, serotonergic, cholinergic, and histamine receptors, which promote the management of a range of symptoms. Clozapine is considered one of the most effective antipsychotics. However, despite its benefits, clozapine …
Schizophrenia is a debilitating mental disorder, which affects approximately 1% of the world population, bringing a significant social and economic burden. Schizophrenia is a multifactorial disease associated with several gene/protein alterations that are highly influenced by environmental factors. Disease symptoms generally manifest in young adults when the neurodevelopment is at its end…
The brain is the most cholesterol-rich organ, accounting for 25% of the total cholesterol present in the human body, and is essential for synaptic transmission. Within the brain, myelin contains the majority of cholesterol, representing 70%, with the other 30% being present in the membranes of neurons and glial cells. Disturbances in cholesterol metabolism and levels are a risk factor for…
(Only some records are available in English at this moment)